| Ident. | Authors (with country if any) | Title |
|---|
| 000168 (2020) |
Tsutomu Takeuchi [Japon] ; Yoshiya Tanaka [Japon] ; Sakae Tanaka [Japon] ; Atsushi Kawakami [Japon] ; Yeong-Wook Song [Corée du Sud] ; Yi-Hsing Chen [Taïwan] ; Mitsuhiro Rokuda [Japon] ; Hiroyuki Izutsu [Japon] ; Satoshi Ushijima [Japon] ; Yuichiro Kaneko [Japon] ; Yoshihiro Nakashima [Japon] ; Teruaki Shiomi [Japon] ; Emi Yamada [Japon] | Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan |
| 000618 (2019-06-12) |
Alain Saraux [France] ; Thomas Barnetche [France] ; Guy Baudens [France] ; Isabelle Idier [France] ; Flore Delaporte [France] ; Pascal Hilliquin [France] | Subcutaneous tocilizumab in monotherapy or in combination with csdmard in patients with moderate to severe rheumatoid arthritis: observational study to describe real-world drug retention rate at 12 months. |
| 000894 (2019) |
Emma L. Simpson [Royaume-Uni] ; Shijie Ren [Royaume-Uni] ; Emma S. Hock [Royaume-Uni] ; John W. Stevens [Royaume-Uni] ; Aymeric Binard [France] ; Yves-Marie Pers [France] ; Rachel Archer [Royaume-Uni] ; Suzy Paisley [Royaume-Uni] ; Matthew D. Stevenson [Royaume-Uni] ; Chloé Herpin [France] ; Salah Ghabri [France] | Rheumatoid arthritis treated with 6-months of first-line biologic or biosimilar therapy: an updated systematic review and network meta-analysis. |
| 000989 (2019) |
Theodora E. Markatseli [Grèce] ; Athina Theodoridou [Grèce] ; Marina Zakalka ; Eftychia Koukli [Grèce] ; Eva Triantafyllidou [Grèce] ; Sotiris Tsalavos [Grèce] ; Alexandros Andrianakos [Grèce] ; Alexandros A. Drosos [Grèce] | Persistence and Adherence during the First Six Months of Tocilizumab Treatment Among Rheumatoid Arthritis Patients in Routine Clinical Practice in Greece. Results from the Single Arm REMISSION II Study (NCT01649817) |
| 000E79 (2019) |
Emma C. De Moel [Pays-Bas] ; Jürgen Rech [Allemagne] ; Michael Mahler [États-Unis] ; Johannes Roth [Allemagne] ; Thomas Vogl [Allemagne] ; Anne Schouffoer [Pays-Bas] ; Robbert J. Goekoop [Pays-Bas] ; Tom W. J. Huizinga [Pays-Bas] ; Cornelia F. Allaart [Pays-Bas] ; René E. M. Toes [Pays-Bas] ; Georg Schett [Allemagne] ; Diane Van Der Woude [Pays-Bas] | Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs |
| 001047 (2019) |
Caroline Ming ; John Stack | 55. A case for continuing tocilizumab beyond 12 months in giant cell arteritis? |
| 001069 (2018-10-19) |
P. Hilliquin [France] ; T. Barnetche [France] ; G. Baudens [France] ; R. Niarra [France] ; I. Idier [France] ; A. Saraux [France] | Subcutaneous Tocilizumab in Monotherapy or in Combination with DMARD in Patients with Moderate to Severe Active Rheumatoid Arthritis: Observational Study to Describe Real-World Drug Retention Rate at 12 Months, Interim Analysis |
| 001144 (2018) |
Maxime Samson [France] ; Hervé Devilliers [France] ; Kim Heang Ly [France] ; François Maurier [France] ; Boris Bienvenu [France] ; Benjamin Terrier [France] ; Pierre Charles [France] ; Loïc Guillevin [France] ; Jean-François Besancenot [France] ; Eric Liozon [France] ; Anne Laure Fauchais [France] ; Romaric Loffroy [France] ; Christine Binquet [France] ; Sylvain Audia [France] ; Raphaèle Seror [France] ; Xavier Mariette [France] ; Bernard Bonnotte [France] | Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study. |
| 001627 (2017) |
Timothy Beukelman [États-Unis] ; Yukiko Kimura [États-Unis] ; Norman T. Ilowite [États-Unis] ; Kelly Mieszkalski [États-Unis] ; Marc D. Natter [États-Unis] ; Grendel Burrell [États-Unis] ; Brian Best [États-Unis] ; Jason Jones [États-Unis] ; Laura E. Schanberg [États-Unis] | The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months. |
| 001812 (2017) |
Graeme Jones [Espagne] ; Thomas Wallace [Espagne] ; Matthew J. Mcintosh [Espagne] ; Laura Brockwell [Espagne] ; Juan J. G Mez-Reino [Espagne] ; Anthony Sebba [Espagne] | Five-year Efficacy and Safety of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Methotrexate- and Biologic-naive or Free of Methotrexate for 6 Months: the AMBITION Study. |
| 001869 (2017) |
Yusuke Miwa [Japon] ; Mayu Saito [Japon] ; Hidekazu Furuya [Japon] ; Ryo Yanai [Japon] ; Yuzo Ikari [Japon] ; Tomoki Hayashi [Japon] ; Tsuyoshi Kasama [Japon] ; Yoichi Toyoshima [Japon] ; Katsunori Inagaki [Japon] | Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission after Six Months of Non-tumor Necrosis Factor Biological Disease-Modifying Antirheumatic Drugs (DMARDs) Treatment. |
| 002438 (2014) |
Paul Emery [Royaume-Uni] ; Gerd R. Burmester [Allemagne] ; Vivian P. Bykerk [États-Unis] ; Bernard G. Combe [France] ; Daniel E. Furst [États-Unis] ; Emilie Barré [Belgique] ; Chetan S. Karyekar [États-Unis] ; Dennis A. Wong [États-Unis] ; Tom W J. Huizinga [Pays-Bas] | Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period |
| 002774 (2013) |
Sylvain Mathieu [France] ; Marion Couderc [France] ; Baptiste Glace [France] ; Bruno Pereira [France] ; Anne Tournadre [France] ; Jean-Jacques Dubost [France] ; Martin Soubrier [France] | Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis |
| 002934 (2013) |
A. A. Marques [Portugal] ; R. Ferreira [Portugal] ; T. Santiago [Portugal] | THU0459-HPR Anxiety and depression scores reduction after six-months of biology therapy |
| 002E01 (2013) |
G. Jones [Australie] ; A. Sebba ; A. Anisfeld [États-Unis] ; J. Devenport [États-Unis] ; C. Bernasconi [Suisse] ; D. Smart [Royaume-Uni] ; D. Galindez [États-Unis] ; C. Mpofu [Suisse] ; J. Gomez-Reino [Espagne] | FRI0248 Long-term efficacy and safety of tocilizumab (TCZ) monotherapy in patients (PTS) with rheumatoid arthritis (RA) previously methotrexate (MTX) naive or mtx free for 6 months prior to study start |
| 002F01 (2013) |
V. Rantalaiho ; H. Kautiainen ; M. Korpela ; S. J Rvenp [Finlande] ; M. Leirisalo-Repo | FRI0092 Disease activity at three months is an excellent predictor of long-term treatment failure in actively treated rheumatoid arthritis patients, 5-year results of the neo-raco trial |
| 002F98 (2013) |
M. Nu Ez ; E. Nu Ez ; S. Sastre ; J. Segur ; L. Lozano ; C. Nicodemo [Espagne] ; F. Maculé ; A. Saul [Espagne] | AB0780 Cost utility analysis of total knee replacement in obese patients with osteoarthritis. prospective study with 12 months follow up |
| 003056 (2013) |
R. Marques ; F. Ramos ; I. Perpétuo ; S. Fernandes ; A. C. Furtado ; A. F. Mourão ; F. Martins [Portugal] ; J. E. Fonseca ; J. A. Pereira Da Silva | AB0696 Predictors of poor response to 6-months methotrexate therapy in a juvenile idiopathic arthritis cohort of patients |
| 003088 (2013) |
R. Westhovens [Belgique] ; J. Wollenhaupt [Allemagne] ; J. J. Gomez Reino [Espagne] ; W. Grassi [Italie] ; M. Le Bars ; C. Gaillez ; C. Poncet [France] ; A. Elegbe [États-Unis] ; J. S. Smolen [Autriche] | AB0568 Efficacy of abatacept in patients with early (≤6 months) RA: Results from agree post-hoc analysis |
| 003119 (2013) |
I. Bouaddi [Maroc] ; H. Rkain [Maroc] ; S. Aktaou [Maroc] ; H. Raissouni [Maroc] ; L. Traki [Maroc] ; L. Bouazzaoui [Maroc] ; B. Benchakroun [Maroc] ; L. Benbrahim [Maroc] ; S. Rostom [Maroc] ; F. Allali [Maroc] ; R. Bahiri [Maroc] ; B. Amine [Maroc] ; K. Benbouazza [Maroc] ; N. Hajjaj-Hassouni [Maroc] | AB0536 Tocilizumab offers clinical and ultrasonographic improvement in rheumatoid arthritis patients. Results of a 6 months follow-up study |
| 003195 (2013) |
M. Schiff [États-Unis] ; R. Alten [Allemagne] ; M. Weinblatt [États-Unis] ; P. Nash [Australie] ; R. Fleischmann [États-Unis] ; P. Durez [Belgique] ; J. Kaine ; I. Delaet ; S. Kelly ; M. Maldonado ; S. Patel ; M. Genovese [États-Unis] | AB0323 Weekly subcutaneous abatacept confers comparable onset of treatment response and magnitude of efficacy improvement over 6 months when administered with or without an intravenous abatacept loading dose |
